Fig. 12From: In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line3D and 2D binding mode of Gefitinib in the active site of EGFR receptorBack to article page